| Gong, Wei |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
NCT04078230: Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 168 | US, RoW | Extend LymphAdenectomy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intrahepatic Cholangiocarcinoma | 12/27 | 12/27 | | |
